BioSpace News Archive

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release first quarter 2023 financial results after the market closes on Monday, May 8, 2023.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) announced today that it plans to host a conference call on Thursday, May 4, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended March 31, 2023.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 10,600 restricted stock units to four newly-hired employees, with a grant date of April 30, 2023.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the 2023 Bank of America Securities Healthcare Conference.

CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets.

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023.

Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura® (ruxolitinib) cream 1.5% to control pruritus (itching) and reduce disease severity in adult patients with atopic dermatitis (AD), the most common type of eczema.

MDxHealth SA, a commercial-stage precision diagnostics company, announced it will release its financial results for the first quarter ended March 31, 2023, after market close on Monday, May 15, 2023.

Cytokinetics, Incorporated announced that on April 28, 2023 it granted stock options to purchase an aggregate of 97,550 shares of common stock to 5 new employees, whose employment commenced in April 2023, as a material inducement to their employment.

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the Annual Aegis Virtual Conference being held May 2-4, 2023.